Report Package: Hot targets for empowered antibody and cell therapy technologies

Report Package: Hot targets for empowered antibody and cell therapy technologies

  • December 2016 •
  • 202 pages •
  • Report ID: 4461538

Report Package: Hot targets for empowered antibody and cell therapy technologies


This package contains three reports analyzing



  • BCMA,

  • CD123 and

  • CD22


as versatile and hot targets for the successful application of empowered antibody and cell technologies, including:



  • Fc-Engineered Antibodies;

  • Radioimmunotherapy;  

  • Immunotoxins;

  • Antibody-Drug Conjugates;

  • T-Cell Redirecting Bispecific Antibodies;

  • Chimeric Antigen Receptor (CAR) T-Cells.


The reports describe and discuss



  • Target background, scientific rationale & expression profiles;

  • Preclinical proof-of-concept;

  • Clinical experience;

  • Competitive landscape;

  • Drug or cell therapy profiles;

  • Company profiles.


Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:


B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities


CD123: a paradigmatic target for immunotherapeutic treatment modalities


CD22: a suitable antigen for targeted payload delivery by immunotherapeutics


Industry=BiologicalTherapy ParentIndustry=LifeSciences Date=201612 Publisher=LaMeriePublishing Price=2000